CCCC - CIK 0001662579
C4 Therapeutics, Inc. trades as CCCC. In its fiscal 2025 annual report the company posted revenue of $35.95M, up 1.0% from the prior year and net income of -$104.99M. This page tracks C4 Therapeutics, Inc. through 516 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 4 fiscal years C4 Therapeutics, Inc.'s revenue declined from $45.78M to $35.95M, a compound annual decline rate of 5.9%. Net profit margin compressed from -183.2% to -292.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-19 |
| Major company event | 8-K | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
The largest companies sharing C4 Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
C4 Therapeutics, Inc. reported revenue of $35.95M for fiscal year 2025, an increase of 1.0% year over year.
In its latest fiscal year C4 Therapeutics, Inc. reported a net loss of $104.99M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.